» Articles » PMID: 19277478

RNA Interference Against Biot2, a Novel Mouse Testis-specific Gene, Inhibits the Growth of Tumor Cells

Overview
Publisher Biomed Central
Date 2009 Mar 12
PMID 19277478
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Biot2 is a novel murine testis-specific gene that was first identified using the SEREX technique, and named by our laboratory. Using conventional RT-PCR and real time RT-PCR, we tested the expression profile of Biot2 in normal tissues and various murine tumor cell lines. Using RNA interference, we studied the biological function of Biot2 in tumorigenesis. We applied various types of growth assay, such as the in vitro MTT, colony-forming and BrdU incorporation assays, along with in vivo tumorigenicity assays, to reveal its inhibition of tumor cell proliferation. The results revealed that the Biot2 transcript was detected only and strongly in the testis tissues and abundantly in five types of murine cancer cell line. Treating B16 murine melanoma, LL/2 murine Lewis lung carcinoma and CT26 murine colorectal adenocarcinoma with special shRNA targeting Biot2 can significantly reduce the proliferation rate of these three tumor cell lines in vitro, as measured by the MTT, colony-forming and BrdU incorporation assays. The tumorigenicity of the CT26 cells transfected with special shRNA targeting Biot2 was also decreased distinctly in vivo compared with the control. It was therefore concluded that Biot2 plays a key role in tumorigenesis and could be a potential target for biotherapy.

Citing Articles

RNA interference of Biot2 induces G1 phase arrest and apoptosis in mouse colorectal cancer cell line.

Zhou C, Zhang P, Xu G, Wu D, Liu R, Zeng Q Oncol Res. 2015; 22(2):93-103.

PMID: 25706396 PMC: 7838428. DOI: 10.3727/096504014X14146137738583.


Antitumor and anti-angiogenesis immunity induced by CR-SEREX-identified Xenopus RHAMM.

Yang H, Zhang D, Deng H, Peng F, Wei Y Cancer Sci. 2010; 101(4):862-8.

PMID: 20704574 PMC: 11159049. DOI: 10.1111/j.1349-7006.2009.01473.x.

References
1.
Valmori D, Souleimanian N, Tosello V, Bhardwaj N, Adams S, ONeill D . Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A. 2007; 104(21):8947-52. PMC: 1885608. DOI: 10.1073/pnas.0703395104. View

2.
Scanlan M, Gure A, Jungbluth A, Old L, Chen Y . Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002; 188:22-32. DOI: 10.1034/j.1600-065x.2002.18803.x. View

3.
Simpson A, Caballero O, Jungbluth A, Chen Y, Old L . Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005; 5(8):615-25. DOI: 10.1038/nrc1669. View

4.
Jager D, Filonenko V, Gout I, Frosina D, Eastlake-Wade S, Castelli S . NY-BR-1 is a differentiation antigen of the mammary gland. Appl Immunohistochem Mol Morphol. 2007; 15(1):77-83. DOI: 10.1097/01.pai.0000213111.05108.a0. View

5.
Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D . Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A. 2006; 103(39):14453-8. PMC: 1570182. DOI: 10.1073/pnas.0606512103. View